Won't you come on in? How to favor lymphocyte infiltration in tumors (Q41474524)

1 October 2017

Won't you come on in? How to favor lymphocyte infiltration in tumors (English)

1 reference

1 October 2017

3

1 reference

1 October 2017

Arianna Calcinotto

2

0 references

Matteo Bellone

object named as

Matteo Bellone

series ordinal

1

0 references

publication date

1 September 2012

1 reference

1 October 2017

1 reference

1 October 2017

1

1 reference

1 October 2017

6

1 reference

1 October 2017

986-988

1 reference

Targeted drug delivery and penetration into solid tumors

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489769

Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer

11 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489769

Targeting the tumour vasculature: insights from physiological angiogenesis

11 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489769

Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer

11 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489769

A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism

11 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489769

Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy

11 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489769

Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors.

11 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489769

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

11 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489769

Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13).

11 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489769

Targeting TNF- to Neoangiogenic Vessels Enhances Lymphocyte Infiltration in Tumors and Increases the Therapeutic Potential of Immunotherapy

11 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.4161%2FONCI.20213

21 January 2018

Identifiers

DOI

10.4161/ONCI.20213

1 reference

release_kcbulgbhf5huhhrgeoqdhl44ky

1 October 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kcbulgbhf5huhhrgeoqdhl44ky

mapped directly with Wikidata item

24 November 2022

based on heuristic

PMC publication ID

3489769

1 reference

PMC publication ID

3489769

1 October 2017

PubMed publication ID

23162781

1 reference

PMC publication ID

3489769